Allergan and Kaya Skin Clinic announce BOTOX tie-up
13 Nov 2008
BOTOX , the non-surgical cosmetic procedure brand and Kaya Skin Clinic, announced a tie-up on BOTOX, and announced the launch of a ''BOTOX at KAYA'', a brand that gives the consumers the assurance of the quality, safety, delivery of the latest and most advanced technologies in aesthetics.
The tie-up between these two leaders in the arena of beauty through science seeks to make available to the Indian woman a truly world class BOTOX experience for the restoration and creation of beauty.
BOTOX is the flagship brand of Allergan Inc, USA- one of the best multi-specialty health care companies in the world. Allergan, Inc. is a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential - to see more clearly, move more freely, and express themselves more fully. In India, Allergan, Inc is represented through Allergan India Pvt. Ltd.
Kaya has 68 clinics in India spread across 20 cities. It is the largest chain of beauty destinations in the Middle East.
''BOTOX is both an art as well as science. BOTOX at Kaya will be the personification of best practices in the use of BOTOX for restoration and creation of beauty for the Indian woman, and would seek to deliver world class quality of BOTOX delivery right here in India. Doctors at Kaya have been specially trained on delivering optimal outcomes with BOTOX, with a clear focus on maximising consumer satisfaction,'' said Raghu Kumar, managing director, Allergan India.,
At Kaya, the consumers will also have the confidence of knowing that they are getting the best quality of BOTOX.''
''Looking good is no more a vanity but a necessity in today's beauty and wellness conscious world. The Indian Woman consumer today is highly beauty conscious, and clearly wants nothing but the best,'' Rakesh Pandey, CEO Kaya Ltd, added.
Allergan India Private Ltd, based in Bangalore, began operations in 1995 and within three years established itself as a leader in ophthalmology. A joint venture between Allergan Inc. and Piramal Healthcare Ltd., the company has a nation-wide distribution channel supplying Eyecare products.
While the pharmaceutical products are manufactured in a state-of-the-art facility in India, other products are imported from overseas plants. Their focus is to deliver international quality products and technology at affordable "Indian" prices.
